#1Nestlé investor seminar 2022 Medical Nutrition Solutions to address specific medical needs Anna Mohl CEO of International Business Nestlē HealthScience®#2Disclaimer This presentation contains forward looking statements which reflect Management's current views and estimates. The forward looking statements involve certain risks and uncertainties that could cause actual results to differ materially from those contained in the forward looking statements. Potential risks and uncertainties include such factors as general economic conditions, foreign exchange fluctuations, competitive product and pricing pressures and regulatory developments. 2 This presentation contains certain financial performance measures which are not defined by IFRS. Management believes that these non-IFRS measures provide additional useful information to assess the financial and operational performance of the Group. Such measures may not be comparable to similar measures presented by other companies and are explained and/or reconciled with our IFRS measures (Consolidated Financial Statements) in the Nestlé Group Alternative Performance Measures (APMs) document available on our Investor Website. November 29, 2022 Nestlé investor seminar 2022#3Broad portfolio to address diverse patient needs across care settings Strong brands under-pinned by scientific expertise 2 Acute Care / Adult Medical Care FOR TUBE FEEDING ONLY For Tube Feeding Only IMPACT Peptide Compleat IMPACT Peptide Jntery N Compleat Organic Blends 269 PLANT-BASED resource ACTIV November 29, 2022 N resource ACTIV Pediatric Care Althéra AMO D PEPTAMEN PEPTAMEN Janis Janio 1.5 Compleat Organic Blends NOW Alfaré MO 3 Neste Nöste PEPTAMEN nutren Junio Junio Compleat pediatric Organic Blends Compleat Organic Blends NE Alfamino BOOS Compleat pediatric Organic Blends ONCHEN GARDEN BE Code In-born Errors of Metabolism sphere Vitaflo R K-Vita sphere Renastart NWT/POIDS NET 44 sphere liquid Ay/2.500 glycosade Pro Metabolic Health OPTIFASTE Bar Berry Crunch 08=0 Pronokal And NEW Pronoka Neste nutren GlucoSmart OPTIFASTE Soup Vegetable mulberry wa OPTIFAST Shule Assorted Kal Nave BOOST cose Contr 16 40 OPTIFASTE Dessert Lemon Crime OPTIFAST Shule High Provin Fa SANA-FIT Now BOOS Cecose Cont 16 BOOST cose Contr 16 a VAN Gastrointestinal NOSUS PEPTAMEN IBD FOR TUBE FEEDWONLY PEITAMEN PEPTAMEN 2.0 ENTERAL Nestle MODULEN FOR TURE FEEDING ONLY PEPTAMEN PEPTAMEN 18 PEPTAMEN PEPTAMEN INTENSE Janie s MODULife Nestlé investor seminar 2022#4Building on a long history of Medical Nutrition expertise 3 Nestlē 1866 November 29, 2022 1960s NASA VIVONEX Nestle Vivonex RTF Completa 400% bie vedu med fo UNFLAVORED 域版图西路 Clintec 1986 1996 Nestle CLINICAL NUTRITION NOVARTIS Clinical Nutrition 2007 2010 Vitaflo Nestlē HealthScience 2011 Nestlé investor seminar 2022#5Medical Nutrition is a large growing category, meeting diverse needs 4 Category is large, with solid growth ~ 5% CAGR CHF 11 bn 4% CAGR 2018 Serving both adults and pediatrics Adults 75% CHF 12 bn Pediatrics 25% 2021 6% CAGR CAGRS are 2022-26. Source: 2021 financial reports, market data and internal analysis November 29, 2022 Market share Company profile 31% Abbott Competitive landscape 19% 4% CAGR NHSc 18% Danone Fresenius Medical Consumer Consumer Medical 6% Split between oral and tube feeding Tube feed 48% Oral 52% 5% CAGR Nestlé investor seminar 2022#6Providing treatment in institutions and at home Usage initiated by Health Care Professional 5 Patient November 29, 2022 Wellness f r Physician Hospital Clinic Prevention Pharmacy Specialty store Treatment 圆 E-commerce Hì Nursing home 11.A Home/community Nestlé investor seminar 2022#7Specialized products governed by specific regulatory framework Leveraging our expertise to manage complex requirements 6 Specialized products for the nutritional management of diseases to be used under medical supervision Examples: • Malnutrition ● Elective surgeries Short bowel syndrome Crohn's disease • Inborn Errors of Metabolism Cognitive impairment ● ● November 29, 2022 Specific regulations: ● Complex and non-harmonized regulatory route-to-market worldwide ● • Specific capabilities and expertise to support approval process ● High standards for scientific substantiation of claims Nestlé investor seminar 2022#8Covered by a spectrum of payment models globally 7 Ou November 29, 2022 In hospital At home Full Reimbursement / coverage by health authorities or private insurance )0€ Partial 0 None 6 Nestlé investor seminar 2022#9Addresses critical healthcare issues and macro trends Creating significant growth opportunities 8 Rising chronic conditions 6 in 10 Adults in the U.S. have a chronic disease 41% 8888 4 in 10 Increased health ownership patients take some degree of action in their own health November 29, 2022 Adults in the U.S. have two or more Aging population Projected global population aged 60 years or over 0.5 bn 1 bn 2.1 bn 1990 2017-2050 - 1980 3.1 bn Pressure on health spending Healthcare expenditure relative to GDP 2000 - 2100 ➜ 14% 10% 6% 2020 Pediatric allergy prevalence 7.7% China 7.6% US 7.1% Canada 7.1% Number of scientific and human studies related to nutrition UK 5.1% Japan 4.7% France 3.8% Australia 3.5% Germany Demand for evidence & data Nestlé investor seminar 2022#10Malnutrition impacts quality of life and creates economic burdens, costing 3x more than for a well-nourished patient 9 Rates of malnutrition ii ↑|| November 29, 2022 Patients in hospital Patients with cancer Elderly Related co-morbidities Decreased quality of life Increased complications Increased mortality Longer recovery time Increased hospital stay Economic impact $58 bn / year Similar impact in other regions Nestlé investor seminar 2022#11Medical Nutrition improves quality and cost of care 10 Return on investment for every dollar spent on Oral Nutritional Supplements (ONS) - hospital € $52 return on investment for every $1 spent on Oral Nutritional Supplements $90 Average cost of ONS per inpatient episode* Source: Philipson et al. Am J Manag Care November 29, 2022 $5 000 Estimated cost saving per inpatient episodes with ONS *Including labor and administrative expenses 米 Nestle Nosto Althéra HMO. 400g Dietary management www protein aleg GRE Infant & children with mild to moderate cow's milk protein allergy £10 m annual savings to NHS in first line treatment Nestlé arginaid EXTRA Arginine-Intensive r Orange Burst + IMPACT Nestle IMPACT 0217 ne Gastrointestinal cancer patients undergoing surgery Decreases costs of hospital stay by~ CHF 2 000 per patient Wound healing patients Cost savings of ~ $1 500 per patient in the early treatment of pressure ulcers Nestlé investor seminar 2022#12Leveraging multi-faceted demand generation and route-to-market 11 Health Care Professional engagement Partnerships November 29, 2022 Patient / consumer-centric Patient / caregiver engagement Channel / route-to-market Nestlé investor seminar 2022#13Shared capabilities across the portfolio 12 Consumer Care Health Care Professional / pharmacist recommendations Health Care Professional & patient education Commercial: customers, channels November 29, 2022 Digital | | Patient starts / prescriptions E-commerce Continuity of care across the continuum | | Medical Affairs: Key Opinion Leaders, | conferences | Medical Nutrition Omni-channel Medical & scientific credibility Consumer & patient insights / patient journey | Sales force: capabilities, call points, I execution Regulatory expertise R&D, technology innovation Market access Nestlé investor seminar 2022#14Leadership in selected segments and geographies, with continued opportunity for market share gains 13 Sources: external data providers and competitive reports; MAT 2022 November 29, 2022 Medical nutrition Pediatric allergy Brazil France Spain U.S. Türkiye AR China Germany (Mexico UK Australia Medical Nutrition excluding Allergy and Inborn Errors of Metabolism Market share 46% 34% 26% 36% 26% 48% 24% 14% 18% 16% Rank 1 1 1 23 -2233 1 W N Nestlé investor seminar 2022#1514 逃 Boosting growth in the core Digital acceleration Win with data November 29, 2022 Key pillars Omni-channel Source Euromonitor, Nutrition Business Journal, IRI Omni-channel commercial execution drives success Hybrid sales force model Tech transformation 北 #1 Oral Nutritional Supplement brands in pharmacy with +12% prescriptions Increased account coverage 15% growth on Oral Nutritional Supplements 20% Medical Nutrition growth Nestlé investor seminar 2022#1615 逃 ORIGINAL ARTICLE Journal of Neurochemistry JOURNAL OF NEUROST Partner with research universities: Drug Resistent Epilepsy JNC The ketogenic diet component decanoic acid increases mitochondrial citrate synthase and complex I activity in neuronal cells Sean David Hughes, Marta Kanabus, Glenn Anderson,; lain P. Hargreaves. Tricia Rutherford Maura O Donnell, J. Helen Cross,** Shamima Rahman, Simon Eaton and Simon J. R. Heales+ Los C Cal and Molecular Gthi DCL hier of Child Huh, La Che PCOS od for Chilubes NFdei Trus Lim, K MC Great Odd Fand Trust London, UK N Namal Hd for Nandy and Near Temp DOCT of Child Rath, London F Mit Gra Ond St Rapid Fondi Trot Land, IX gry DCL of Child that in UK Aberad The Katogenic diet Daneve tot par to beating phemacopy Hea culties around compliance and tobilly. Co County, there saneadorina simpler formulations at could plate facy of the KD One of the proposed hypothesis that the KD no celular chondial content which was evation of the sure thad Hare we have boused on the medium-chan sighede tom of the diet and the beer vation th on that plama ocenoic acid (C) and decancic acid (C10) are vad in patients on the medumchainsighede ne-SYSY), KD. Using a nu that 250-M C10, fut et CB, caused, over-day petoda Boosting growth in the core in the cost of wine la tot in Ho her of menims have been pepand the has changes in hinner er levels, cha GABA, and the metalice gences of the det om ifalar energy Sanke 200 The ing de KD) s ha beeste puters who had epilepy Kanal 2000 Cock deeds be effective atendicing seines in individt al 20 Fredal hip has been als with druge plepsy (Neal o al 2009 Despe poral in the brain of mes fed the KD leading to the the effectiveness of the des, the exact chofsion marked increase in the mitochondrese along with complex activity and case activity hoed mchandal number was so indicated by action me copy C10a pored pesme prostor att receptor ago, and the use of a persone pr activo receptor y antagone was shown to prevent the C10 maduted in in mitochondrial contact Co may the machondrial potation associated with the KD and rases the possibly that foutions based on the fatty acid could replace a more complex diet Keywords: car widget, machonda PPAR (2014) 10111112040 &N C and LUK With peso de la al dynion at the level of the y chainbanded in mal maled as of November 29, 2022 2013 be G U UCL of Cdk M ACADORA LMT, NHS Great Ormond Street Hospital for Children NHS Foundation Trust NHS University College London Hospitals NHS Foundation Trust Vitaflo K K-Vita™ Partnerships with external stakeholders shapes innovation and medical practice Partner with Key Opinion Leaders: COVID-19 ICU Protocol Tube feeding for patients with acute respiratory failure. Feeding protocol. Partner with policy makers: EU Beating Cancer Plan Cancer care: why nutrition matters Malnutrition in cancer patients leads to poorer health outcomes. It also results in an increased burden to healthcare resources. Nutritional care should be an integral part of cancer care. for c Good lu European Commission Why do we need an EU Cancer Plant 4-10. 200 1000 000000 for EUROPE'S BEATING CANCER PLAN LET'S STRIVE FOR MORE Se 3% of and preven wyn car cam 40% Europe's Beating Cancer Plan proposes actions for all stages of the disease Pepe mering Nestlé investor seminar 2022#1716 ● ● ● ● ● ● Boosting growth in the core Winning strategy Market dynamics Aging population Prevalence of major diseases Regulatory dynamics Medical practice shifts Regulatory 9 registration licenses 1st liquid Food for Special Medical Purpose November 29, 2022 1st cancer Food for Special Medical Purpose Building a leader in China Invest in local pipeline Local R&D • Local manufacturing • First liquid Food for Special Medical Purpose plant in China In market execution Scaled medical sales team Health Care Professional education Key Opinion Leader collaboration B #1 in pediatric allergy Noste JL 8 ALFARE ****** BEKE PENT 肽敏舒 ALTHERA SEARC Nestle A PURIORE wwwww 100-1 Nestlé 混敏舒 ALFAMINO SEYRE BERTA #1 in pediatric growth Noste 小佳膳 NUTREN S STAR Nestle Mökit PEPTAMEN SO ESPESSE menrue LAN #1 choice for cancer patients NES 速熠素 -oral- PROVE Nestlé investor seminar 2022#1817 O Market share 15.8% 500 2021 sondolis HP2 kcal Oct '21 November 29, 2022 Boosting growth in the core Clinical evidence to drive differentiated market access and growth Mar '22 45.6% N Clinutren Thicken P W Reinbursement in homecare 2022 42% Jul '22 Market investment and execution drives growth Thicken-Up Clear ● First & only dysphagia product with reimbursement Sondalis 2.0 First hyper- concentrated tube feeding reimbursed in homecare C+ Locally produced products accelerate growth Nun resource energy 25.8% 2019 resource protein Nound resource diabet 25.6% N resource 20-fibre 2020 Nesne resource Junio NHSc Türkiye % market share 26.6% Ne resource Junio Fare 2021 SLAR 27.9% 9M 2022 Nestlé investor seminar 2022#1918 Nestle Alfamino 400g GE Allergy management For the dietary the of alle multiple f and/or Differentiating through insights November 29, 2022 Supports development of the immune system and microbiome of patients with severe cow's milk protein allergies Compleat pediatric PEPTIDE plant-based CAN 1482 Fuel growth through disease specific innovation to address specific patient needs High protein, superior tolerance PEPTAMEN 20 Plant-based A TRIMIZSE Real food to improve tolerance, with microbiome profile, and to meet patient preferences Specialized high protein with better tolerance and nutrient absorption nutren NEW Nestle nutren. GlucoSmart Nutrition concentration mulberry infextract Nestle Diabetes management resource ULTRA RION PROTER Vanita Highest level of protein, improves patient adherence Manage blood glucose levels after meals Nestlé investor seminar 2022#2019 419 20010 ON SOMON Differentiating through insights SimpLink feeding technology November 29, 2022 Cerebral Palsy Health Care Professional & patient platform aned 4kids PEPTAMENT PEPTAMEN Junio 1.5 Junio 0.6 st PEPTAMEN Junio P Innovation beyond products Holistic industry-leading solutions that drive growth G PEPTAMEN No-stie Thicken UP Junio ModuLife® program for Crohn's Disease Patient support app Health Care Professional training & certification Nestlé Nutrition Institute BO Welcome to Nestle Health Science MODULife CONCEN CDED Expert Training I Mini Nutritional Assessment for elderly D go 00 DO 00 To 000 000 67% Ky SOUMAN Nestlé investor seminar 2022#21Key takeaways 20 November 29, 2022 06 Nestlé investor seminar 2022#22Our leadership journey on nutrition and health 3 strategic imperatives Boosting growth in the core Expanding geographically, enhancing category leadership and building customer partnerships Differentiating through insights Understanding consumer/patient needs, leveraging R&D capabilities and innovation ecosystem Unlocking growth via portfolio management Strengthening leadership through M&A and delivering on acquisition and synergy plans 21 November 29, 2022 Driving further value creation to 2025 Grow organically at a high single-digit rate Strong category momentum and share gains International expansion Science and innovation ● Reach underlying TOP margin of > 18% Synergy delivery Leverage from strong organic growth Efficient use of resources Nestlé investor seminar 2022#23Overall: Key takeaways 22 Nestlē HealthScience November 29, 2022 1 Operate in attractive categories with long-term growth trends 2 Strong portfolio focused on nutrition and metabolism 3 Unique scale and leadership 4 Powerful synergies between Consumer Care and Medical Nutrition Nestlé investor seminar 2022